Impact of statin treatment on 1-year functional and histologic renal allograft outcome

被引:36
作者
Masterson, R [1 ]
Hewitson, T
Leikis, M
Walker, R
Cohney, S
Becker, G
机构
[1] Royal Melbourne Hosp, Dept Nephrol, Parkville, Vic 3050, Australia
[2] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia
关键词
statin; renal transplant; chronic allograft nephropathy;
D O I
10.1097/01.tp.0000168941.19689.cf
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Statins are antilipidemic agents that exhibit a variety of cellular effects independent of their lipid-lowering action. A retrospective study was undertaken to establish the impact of statins on graft outcome in the first year posttransplantation. Methods. Data from patients with uniform immunosuppression (cyclosporine, mycophenolate mofetil, and prednisolone) who underwent transplantation at the authors' unit from 1997 to 2002 were reviewed. Patients prescribed statins were compared with those not on a statin. Mean change in creatinine clearance (CrCl) from 3 to 12 months posttransplantation was calculated. Histomorphometric analysis was used to quantify fractional interstitial area and collagen III deposition in matched preperfusion and 12-month protocol biopsy specimens. Results. Seventy-seven patients met study criteria: statin, n=44 patients; nonstatin, n=33 patients. Median time to commencing a statin was 5 weeks. At 3 months, CrCl (+/- SEM) was similar: 51.6 +/- 2.9 mL/min (statin) versus 51.3 +/- 1 mL/min (nonstatin). At 12 months, the mean change in CrCl was 4.1 +/- 1 mL/min (statin) compared with -2.0 +/- 1.8 mL/min (nonstatin), resulting in a difference of 6.13 mL/min at 12 months (P < 0.005). Mean preperfusion fractional interstitial areas were similar (23.9 +/- 1.6%; P=not significant [NS]). On 12-month biopsy specimens, the fractional interstitial area had increased to 34 +/- 3.2% in the nonstatin group (P < 0.005), with no change in the statin group. Interstitial collagen III deposition was similar in preperfusion biopsyspecimens (10.4 +/- 1%; P=NS), but at 12 months it was significantly greater in the nonstatin group (17.6 +/- 1%; P < 0.05) Conclusions. Early introduction of statins may be associated with improved 1-year graft outcome.
引用
收藏
页码:332 / 338
页数:7
相关论文
共 45 条
[1]   Atorvastatin improves endothelial function in renal-transplant recipients [J].
Åsberg, A ;
Hartmann, A ;
Fjeldså, E ;
Holdaas, H .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (09) :1920-1924
[2]   A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [J].
Bianchi, S ;
Bigazzi, R ;
Caiazza, A ;
Campese, VM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (03) :565-570
[3]   PROTEINS REGULATING RAS AND ITS RELATIVES [J].
BOGUSKI, MS ;
MCCORMICK, F .
NATURE, 1993, 366 (6456) :643-654
[4]   SUPPRESSION OF LYMPHOID-CELL FUNCTION-INVITRO BY INHIBITION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE BY LOVASTATIN [J].
CUTTS, JL ;
BANKHURST, AD .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1989, 11 (08) :863-869
[5]   Immunosuppressive strategies in transplantation [J].
Denton, MD ;
Magee, CC ;
Sayegh, MH .
LANCET, 1999, 353 (9158) :1083-1091
[6]   Cell cycle: Routine role for Ras [J].
Downward, J .
CURRENT BIOLOGY, 1997, 7 (04) :R258-R260
[7]   Effect of lipid reduction on the progression of renal disease: A meta-analysis [J].
Fried, LF ;
Orchard, TJ ;
Kasiske, BL .
KIDNEY INTERNATIONAL, 2001, 59 (01) :260-269
[8]   SIMVASTATIN INHIBITS PDGF-INDUCED DNA-SYNTHESIS IN HUMAN GLOMERULAR MESANGIAL CELLS [J].
GRANDALIANO, G ;
BISWAS, P ;
CHOUDHURY, GG ;
ABBOUD, HE .
KIDNEY INTERNATIONAL, 1993, 44 (03) :503-508
[9]   Postischemic acute renal failure is reduced by short-term statin treatment in a rat model [J].
Gueler, F ;
Rong, S ;
Park, JK ;
Fiebeler, A ;
Menne, J ;
Elger, M ;
Mueller, DN ;
Hampich, F ;
Dechend, R ;
Kunter, U ;
Luft, FC ;
Haller, H .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (09) :2288-2298
[10]  
Hariharan S, 2002, TRANSPLANTATION, V73